Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.IMRA · Entity 4024 | SVP, CMO | January 28, 2022 | February 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date January 28, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,100 |
Reported balance
After 2022-01-28 transaction · row 1
1 source rowRow 1 · 2022-01-28 · Grant · Acquired 34,100 · Balance 34,100 F1: The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2032-01-27 | Direct | 34,100 |
Reported balance
After 2022-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-28 · Grant · Acquired 34,100 · Balance 34,100 F2: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date.
F2: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2022 Filed Feb 1, 2022 23:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 34,100 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-22-006037 · doc4.xml · derivative · entry 2 Attie Kenneth · CIK 0001454829 · SVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,100 Underlying: Common Stock · 34,100 shares Expires 2032-01-27 F2 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 23:26 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantCommon Stock | 34,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006037 · doc4.xml · nonDerivative · entry 1 Attie Kenneth · CIK 0001454829 · SVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,100 F1 · shares: The shares underlying the restricted stock unit vest over four years, with 25% of the shares vesting in equal annual installments until the fourth anniversary of the grant date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:14 UTC | Enliven Therapeutics, Inc. IMRA · Entity 4024 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001209191-21-005873 · doc4.xml · derivative · entry 1 Attie Kenneth · CIK 0001454829 · SVP, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.